Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 345 participants.

Also called NCT07387003

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 345 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07387003
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07387003. Randomized; no masking; primary purpose treatment. Start 2026-04-10 (anticipated); primary completion 2027-02-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes (T2DM)
Intervention (Drug)
GZR101-80
Intervention (Drug)
GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30)
Lead sponsor
Gan & Lee Pharmaceuticals. (class: industry)

Record details

Record id
cardio:ct-nct07387003
Content hash
d8ad54c1fc06f013de4c7c82e22feaaa3d54361fea09fc58f9e1643fb289e5d4